(Q50794710)

19 March 2018

title

Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. (English)

1 reference

19 March 2018

1 reference

1 reference

12

J Buell

1 reference

19 March 2018

author name string

G W Neff

1

1 reference

19 March 2018

N Kemmer

2

1 reference

19 March 2018

V C Zacharias

3

1 reference

19 March 2018

T Kaiser

4

1 reference

19 March 2018

C Duncan

5

1 reference

19 March 2018

R McHenry

6

1 reference

19 March 2018

M Jonas

7

1 reference

19 March 2018

D Novick

8

1 reference

19 March 2018

C Williamson

9

1 reference

19 March 2018

K Hess

10

1 reference

19 March 2018

M Thomas

11

1 reference

19 March 2018

language of work or name

English

0 references

publication date

1 December 2006

1 reference

19 March 2018

Transplantation Proceedings

published in

1 reference

19 March 2018

volume

38

1 reference

19 March 2018

issue

10

1 reference

19 March 2018

page(s)

3552-3555

1 reference

19 March 2018

Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.107

Ammonia and hepatic encephalopathy: the more things change, the more they remain the same.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.107

Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.107

Metabolism and brain uptake of gamma-aminobutyric acid in galactosamine-induced hepatic encephalopathy in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.107

Overestimation of serum concentrations of gamma-aminobutyric acid in patients with hepatic encephalopathy by the gamma-aminobutyric acid-radioreceptor assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.107

Management of hepatic encephalopathy: role of rifaximin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.107

Treatment of hepatic encephalopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.107

Treatment of hepatic encephalopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.107

Dispelling myths in the treatment of hepatic encephalopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.107

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.107

Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.107

Intractable Hepatic Encephalopathy After Tips with Polytetrafluoroethylene-covered Stent-Graft

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.107

Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.107

Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.107

10.1016/J.TRANSPROCEED.2006.10.107

7 January 2021

Identifiers

DOI

1 reference

19 March 2018

1 reference

19 March 2018